1- (2- chloroethyl)- 3- (2- (dimethylaminosulfonyl)ethyl)- 1- nitrosourea (tauromustine)
Also Known As:
tauromustine; TCNU
Networked: 39
relevant articles (4 outcomes,
19 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
Related Diseases
1. | Neoplasms (Cancer)
|
2. | Adenocarcinoma
|
3. | Breast Neoplasms (Breast Cancer)
|
4. | Carcinoma (Carcinomatosis)
01/01/1987
- " TCNU produced significantly greater cytotoxicity in the Mer- cells (Walker 256 rat breast carcinoma resistant to nitrogen mustards; human lung carcinoma A427) than in the Mer+ cells (Walker 256 wild-type; human lung carcinoma A594). " 01/01/1987
- " The effect of a novel taurine nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl)ethyl]-1-nitrosour ea (TCNU) on cytotoxicity, DNA crosslinking and glutathione reductase in lung carcinoma cell lines." 09/01/1991
- " The effect of intravenously injected tauromustine (TCNU) on tumor growth and body weight was studied in rats with subcutaneously implanted experimental carcinomas. " 04/01/1988
- " TCNU and its two metabolites were found to exhibit equal or better oral efficacy than that of BCNU, CCNU, MeCCNU or chorozotocin against L1210 leukemia, Walker mammary carcinoma, Lewis Lung, Harding Passey melanoma and colon carcinoma C26. " 05/01/1993
- " Degradable starch microspheres in cytostatic treatment of a liver carcinoma; experimental studies in rats with 5-fluorouracil, tauromustine, carmustine, doxorubicin and RSU-1069."
|
5. | Colorectal Neoplasms (Colorectal Cancer)
|
|
Related Drugs and Biologics
Related Therapies and Procedures